Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.49 |
| ▸ | GPR4 | P46093 | 1/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 4/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30984093 | 0.88 | GPR4 (0.51) | GPR119EPHX2GPR4PDE3BPDE3A | |
| SCHEMBL31269123 | 0.88 | GPR4 (0.51) | GPR119EPHX2GPR4PDE3BPDE3A | |
| SCHEMBL30983866 | 0.88 | KDM4E (0.51) | GPR119EPHX2GPR4PDE3BPDE3A | |
| SCHEMBL31268813 | 0.87 | DRD3 (0.53) | GPR119EPHX2GPR4PDE3BPDE3A | |
| SCHEMBL30983991 | 0.86 | GPR119 (0.48) | GPR119EPHX2GPR4DRD3RXFP1 | |
| SCHEMBL31269031 | 0.85 | GPR4 (0.47) | GPR119EPHX2GPR4PDE3BPDE3A | |
| SCHEMBL13662434 | 0.83 | GPR119 (0.45) | GPR119 | |
| SCHEMBL1673377 | 0.82 | GPR4 (0.53) | GPR119EPHX2GPR4DRD3DRD2 | |
| SCHEMBL1730771 | 0.82 | HRH2 (0.58) | GPR119EPHX2GPR4DRD3DRD2 | |
| SCHEMBL31269095 | 0.82 | RXFP1 (0.45) | GPR119EPHX2GPR4RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| US-12414954-B2 | POLQ inhibitors | ASTRAZENECA AB (SE) | 2025-09-16 | — | — | US | disclosed |
| US-20250195530-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| US-20240366615-A1 | POLQ INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 2024-11-07 | — | — | US | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366615-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | GPR119 3291/4885EPHX2 3565/4885GPR4 3640/4885 |
| US-12414954-B2 | POLQ inhibitors | POLQ, POLG, POLB | GPR119 3291/4885EPHX2 3565/4885GPR4 3640/4885 |
| US-20250195530-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | GPR119 3291/4885EPHX2 3565/4885GPR4 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.